Skip to content

Prestige Consumer Healthcare

US · PBH #2733 by market cap Listed 1970
49.63 +0.03 +0.06%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.7 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
115.49% +0.68pp
Institutions
393 +10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund101.73%
Public Company6.11%
Hedge Fund4.90%
Individual/Insider1.41%
Government Pension Fund1.25%
Private Company0.67%
Insurance Company0.36%
Family Office/Trust0.19%
Sovereign Wealth Fund0.19%

Top holders as of 2026-09-30

BlackRock 16.58% · 7.86M sh
Ariel Investments, LLC 10.27% · 4.87M sh
Vanguard Portfolio Management, LLC 5.93% · 2.81M sh
Dimensional Fund Advisors 5.59% · 2.65M sh
Fuller & Thaler Asset Management, Inc. 4.92% · 2.33M sh
State Street Global Advisors 4.66% · 2.21M sh
Vanguard Capital Management, LLC 4.53% · 2.15M sh
Brandes Investment Partners, LP 4.33% · 2.05M sh
Kayne Anderson Rudnick Investment Management, LLC 3.95% · 1.87M sh
Geode Capital Management, LLC 2.71% · 1.29M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 21 buys · 28 sells

NameRoleStake
Ronald Lombardi Chairperson & CEO 0.79%
Christine Sacco Chief Financial Officer 0.15%
John Byom Lead Independent Director 0.10%
William P'Pool Senior Vice President 0.09%
Jeffrey Zerillo Former Officer 0.07%
Sheila Hopkins Former Independent Director 0.06%
Adel Mekhail Executive Vice President of Marketing & Sales 0.04%
Mary Fritz Former Senior Vice President of Quality & Regulatory Affairs 0.03%
Dawn Zier Independent Director 0.03%
Clesteen Clark Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-03 John Byom Lead Independent Director Other Acquisition +2,981 --
2026-08-03 Clesteen Clark Independent Director Other Acquisition +2,981 --
2026-08-03 Dawn Zier Independent Director Other Acquisition +2,981 --
2026-08-03 James D'Arecca Independent Director Other Acquisition +2,981 --
2026-08-03 John Kelly Independent Director Other Acquisition +2,981 --
2026-05-10 Jeffrey Zerillo Former Officer Open Market Disposition -351 $52.28
2026-05-06 Christine Sacco Chief Financial Officer Sale to Issuer -991 $54.59
2026-05-06 Ronald Lombardi Chairperson & CEO Sale to Issuer -2,543 $54.59
2026-05-06 Jeffrey Zerillo Former Officer Sale to Issuer -351 $54.59
2026-05-06 Jeffrey Zerillo Former Officer Open Market Disposition -305 $54.36
2026-05-06 Adel Mekhail Executive Vice President of Marketing & Sales Sale to Issuer -487 $54.59
2026-05-05 Jeffrey Zerillo Former Officer Intent to Sell (Form 144) -1,207 $54.99
2026-05-04 Christine Sacco Chief Financial Officer Sale to Issuer -1,267 $55.75
2026-05-04 Ronald Lombardi Chairperson & CEO Sale to Issuer -2,197 $55.75
2026-05-04 Jeffrey Zerillo Former Officer Sale to Issuer -307 $55.75
2026-05-04 Jeffrey Zerillo Former Officer Private Disposition -1,207 $54.99
2026-05-04 Jeffrey Zerillo Former Officer Open Market Disposition -346 $55.32
2026-05-03 Christine Sacco Chief Financial Officer Sale to Issuer -3,434 $55.31
2026-05-03 Christine Sacco Chief Financial Officer Other Acquisition +7,008 --
2026-05-03 Christine Sacco Chief Financial Officer Other Acquisition +11,976 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Prestige Consumer Healthcare discussion 0 comments

Add a comment